Nuvectis Pharma, Inc. Accounts Payable
Nuvectis Pharma, Inc. (NVCT) had Accounts Payable of $5.18 million as of 2026-06-30, per its 10-Q filed 2026-08-04.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current › Accounts Payable and Accrued Liabilities, Current
us-gaap:AccountsPayableCurrent · last filed 2026-08-04
- 2026-06-30: Accounts Payable, Current $5.18M.
- 2026-03-31: Accounts Payable, Current $4.70M.
- 2025-12-31: Accounts Payable, Current $6.27M.
- 2025-09-30: Accounts Payable, Current $6.44M.
| Period end | Accounts Payable, Current |
|---|---|
| 2026-06-30 | $5.18M 10-Q · filed 2026-08-04 |
| 2026-03-31 | $4.70M 10-Q · filed 2026-05-05 |
| 2025-12-31 | $6.27M 10-Q · filed 2026-08-04 |
| 2025-09-30 | $6.44M 10-Q · filed 2025-11-04 |
| 2025-06-30 | $4.98M 10-Q · filed 2025-08-05 |
| 2025-03-31 | $2.99M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $2.50M 10-K · filed 2026-02-11 |
| 2024-09-30 | $2.26M 10-Q · filed 2024-11-05 |
| 2024-06-30 | $1.85M 10-Q · filed 2024-08-06 |
| 2024-03-31 | $1.76M 10-Q · filed 2024-05-07 |
| 2023-12-31 | $2.77M 10-K · filed 2025-02-25 |
| 2023-09-30 | $3.49M 10-Q · filed 2023-11-08 |
| 2023-06-30 | $1.80M 10-Q · filed 2023-08-09 |
| 2023-03-31 | $2.10M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $2.91M 10-K · filed 2024-03-05 |
| 2022-09-30 | $2.25M 10-Q · filed 2022-11-08 |
| 2022-06-30 | $1.43M 10-Q · filed 2022-08-10 |
| 2022-03-31 | $1.35M 10-Q · filed 2022-05-12 |
| 2021-12-31 | $1.06M 10-K · filed 2023-03-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Verastem, Inc. (VSTM) | United States | $0.706B | -1.71 |
| IRONWOOD PHARMACEUTICALS INC (IRWD) | United States | $0.694B | 5.37 |
| Climb Bio, Inc. (CLYM) | United States | $0.683B | -13.03 |
| COLLEGIUM PHARMACEUTICAL, INC (COLL) | United States | $0.737B | 24.57 |
| ZEVRA THERAPEUTICS, INC. (ZVRA) | United States | $0.668B | 14.61 |
| Faeth Therapeutics, Inc. (FTH) | United States | $0.750B | |
| BlossomHill Therapeutics, Inc. (BLSM) | United States | $0.647B | |
| Design Therapeutics, Inc. (DSGN) | United States | $0.766B | -12.78 |
| Shattuck Labs, Inc. (STTK) | United States | $0.634B | -13.30 |
| Wave Life Sciences, Inc. (WVE) | $0.780B | -5.56 |